Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1

Asha M. Rudjord-Levann, Zilu Ye, Lise Hafkenscheid, Sabrina Horn, Renske Wiegertjes, Mathias A.I. Nielsen, Ming Song, Caroline B.K. Mathiesen, Jesse Stoop, Sean Stowell, Per Thor Straten, Hakon Leffler, Sergey Y. Vakhrushev, Sally Dabelsteen, Jesper V. Olsen, Hans H. Wandall*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

6 Citations (Scopus)
46 Downloads (Pure)

Abstract

Galectins are a group of carbohydrate-binding proteins with a presumed immunomodulatory role and an elusive function on antigen-presenting cells. Here we analyzed the expression of galectin-1 and found upregulation of galectin-1 in the extracellular matrix across multiple tumors. Performing an in-depth and dynamic proteomic and phosphoproteomic analysis of human macrophages stimulated with galectin-1, we show that galectin-1 induces a tumor-associated macrophage phenotype with increased expression of key immune checkpoint protein programmed cell death 1 ligand 1 (PD-L1/CD274) and immunomodulator indoleamine 2,3-dioxygenase-1 (IDO1). Galectin-1 induced IDO1 and its active metabolite kynurenine in a dose-dependent manner through JAK/STAT signaling. In a 3D organotypic tissue model system equipped with genetically engineered tumorigenic epithelial cells, we analyzed the cellular source of galectin-1 in the extracellular matrix and found that galectin-1 is derived from epithelial and stromal cells. Our results highlight the potential of targeting galectin-1 in immunotherapeutic treatment of human cancers.

Original languageEnglish
Article number106984
JournaliScience
Volume26
Issue number7
Number of pages21
ISSN2589-0042
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors

Keywords

  • Cancer
  • Immunology

Cite this